Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT07499128
Status
Enrolling By Invitation

Conditions

  • Antibodies Bispecific
  • Body Temperature
  • Cell and Tissue-Based Therapy
  • Cytokine Release Syndrome
  • Cytokines
  • Immune Monitoring
  • Immunotherapy
  • Lymphoma
  • Lymphoma Mantle-cell
  • Monitoring Physiologic
  • Multiple Myeloma
  • Neoplasms
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Receptors Chimeric Antigen
  • Thermometry
  • Wearable Electronic Devices

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • TempTraq — DEVICE
    Continuous temperature monitoring (CTM) wearable patch device
  • VitalTraq — DEVICE
    Multi-vital, multi-sensor smartphone/ tablet application allowing data collection of blood pressure, heart rate, heart rate variability, and respiration rate using Remote Photoplethysmography technology (rPPG)

Study Details

Background: Drugs or cell therapies to treat cancer can sometimes cause cytokine release syndrome (CRS). That is, the body makes too many cytokines after treatment. Cytokines are proteins that play a role in the immune system. CRS can cause fever, chills, fatigue, low blood pressure, or breathing problems. Researchers want to know if continuously monitoring a person s body temperature can help reduce the chance of getting serious CRS. Objective: To learn if an approved patch called TempTraq can detect fever before serious CRS develops. Eligibility: People aged 18 years and older with cancer who are staying at the NIH clinic for treatment with drugs or cell therapies. Design: Participants will receive TempTraq patches and a special NIH tablet. The TempTraq is a small patch applied to clean, dry skin under the arm. It continually monitors body temperature and sends the data to an application on the tablet. Participants will wear the patch most of the time they are admitted to the hospital. They could wear it for up to 15 days. The patch monitoring does not replace regular temperature checks, all participants will still have have their regular temperature checks as part of their treatment plan. Participants may also opt to use VitalTraq, another application on the tablet. They will hold the screen up to their face for about 1 minute. VitalTraq uses the camera in the tablet to measure blood pressure, heart rate, and breathing. They will do this once per day while they are in the clinic; they may do it more often if they have a fever or feel unwell. Blood may be drawn for research. Participants will be asked about their experience within 1 week after TempTraq is removed. Participants who choose to use the patch, complete its use, and return at a later date for another treatment or study, may be able to re-enroll to have the patch used again.

Key Dates

Start date
May 27, 2026
Status verified
May 2026
Primary completion
Jun 30, 2029
Completion
Aug 18, 2029

Study Design

Enrollment
136 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DEVICE_FEASIBILITY

Arms

  • No Intervention: Control Arm 2
    Use of non-readable CTM devices, TempTraq without actionable alerts, and optional use of black-boxed VitalTraq
  • Experimental: Intervention Arm 1
    Use of non-readable CTM devices, TempTraq with actionable alerts, and optional use of black-boxed VitalTraq

Primary Outcome Measure

To assess whether continuous observations of fevers with TempTraq versus intermittent fevers monitoring reduce the risk of progression to grade >= 3 cytokine release syndrome (CRS) [ Time Frame: TempTraq will be worn for up to 15 days inpatient, monitoring for CRS symptoms will continue for a total of 2 months from enrollment ]

Locations (1)

FacilityCityStateZIPSite coordinators
National Institutes of Health Clinical CenterBethesdaMaryland20892-

Find similar trials in Bethesda, MD

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
National Institutes of Health Clinical Center· Bethesda, MD

Related Studies